April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization Related to Multifocal Choroiditis
Author Affiliations & Notes
  • P. Iacono
    Eye Clinic, Fondazione G.B. BIETTI, Rome, Gorizia, Italy
  • M. Battaglia Parodi
    Department of Ophthalmology,,
    University of Udine, Udine, Italy
  • F. Menchini
    Department of Ophthalmology,,
    University of Udine, Udine, Italy
  • I. Zucchiatti
    Department of Ophthalmology,
    University of Udine, Udine, Italy
  • F. Bandello
    Department of Ophthalmology,
    University of Udine, Udine, Italy
  • Footnotes
    Commercial Relationships  P. Iacono, None; M. Battaglia Parodi, None; F. Menchini, None; I. Zucchiatti, None; F. Bandello, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1871. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Iacono, M. Battaglia Parodi, F. Menchini, I. Zucchiatti, F. Bandello; Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization Related to Multifocal Choroiditis. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1871.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the effects of intravitreal bevacizumab (Avastin) injections in the treatment of choroideal neovascularization (CNV) associated with multifocal choroiditis (MC).

Methods: : Prospective interventional case series. Patients with MC complicated by subfoveal CNV underwent a complete ophthalmologic examination, including ETDRS visual acuity, optical coherence tomography (OCT), fluorescein angiography, and indocyanine green angiography. The protocol required 3 monthly consecutive injections, followed by repeated injections as needed. The planned follow-up was 12 months.

Results: : Ten patients were enrolled in the study and prospectively followed up. Mean visual acuity and mean foveal thickness (FT) at the baseline were 0.58±0.48 (logMAR±SD) and 290±92µm SD, respectively. At the 3-month examination, mean visual acuity improved to 0.42±0.48 and mean FT decreased to 298±172µm SD. At the 12-month examination, mean visual acuity was 0.40±0.49, and mean FT was 255±163µm. No side-effect or complication was registered.

Keywords: choroid: neovascularization • chorioretinitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×